REVIEWED BY
Marcus Reinhardt — Chemical Researcher, Lead Analyst & Peptide Research Advisor
Marcus Reinhardt is a chemical researcher specializing in sustainable materials and advanced formulation science, with research experience in compound development and health optimization. He reviews all Peptide Insider educational content for scientific accuracy, strength of supporting evidence, and practical relevance. Editorial team.
Quick Summary
The Wolverine stack peptide is the common market name for BPC-157 and TB-500 sold or run together. The name comes from the comic-book healing factor, not from any research designation, and no study has ever tested the two compounds as a combination. What exists is two separate preclinical literatures that happen to describe complementary mechanisms: BPC-157 is associated with angiogenesis, TB-500 with cell migration. Both were recommended for the FDA’s Section 503A bulk drug substances list in July 2026, and neither is legal to compound today. This guide covers what is in the stack, what the evidence does and does not support, how to verify a blended vial, and where the pairing sits after the 2026 regulatory changes.
Key Takeaways
- Wolverine stack means BPC-157 plus TB-500. The name is market shorthand, not a formulation standard, and the exact ratio varies by vendor.
- No study has tested the combination. The synergy argument is an inference drawn from two separate preclinical literatures.
- Both components cleared the FDA’s Pharmacy Compounding Advisory Committee in July 2026, each by a vote of 8 to 6 with one abstention. Neither is compoundable until rulemaking finishes, which practitioners estimate at 12 to 24 months.
- A pre-blended vial is harder to verify than two single vials, because one aggregate purity figure cannot demonstrate that both components are present at the stated ratio.
- Both compounds are unapproved drug substances. Research-grade material is sold for laboratory use only.

What Is the Wolverine Stack?
The Wolverine stack is BPC-157 and TB-500 used together. That is the whole definition, and it is worth stating plainly because the name obscures it.
The label comes from the Marvel character whose defining trait is rapid tissue regeneration. It originated in forums and vendor catalogs, not in any published work, and it carries no formulation specification: there is no standard ratio, no standard vial mass, and no body that defines what may be sold under the name. Two vendors selling a Wolverine blend may be shipping meaningfully different products.
This matters more than it sounds. The research peptide market has developed a habit of naming combinations after their marketing promise rather than their contents, and the names travel faster than the specifications behind them. Glow and KLOW follow the same pattern. In each case the practical question is identical: what is in the vial, at what ratio, and who verified it. Add GHK-Cu and KPV to this pair and you get KLOW, covered in our klow peptide guide.
What Is Actually in It
BPC-157 is a pentadecapeptide, meaning fifteen amino acids, derived from a sequence found in a protein present in human gastric juice. It is the more heavily studied of the two, with a large rodent literature covering tendon, ligament and gastrointestinal injury models. Full detail is in our BPC-157 scientific review.
TB-500 is a synthetic peptide corresponding to an active region of thymosin beta-4, a naturally occurring 43-amino-acid protein involved in actin regulation. TB-500 is a fragment of that protein, not the protein itself, and the distinction matters when reading both research and certificates of analysis. Our TB-500 guide covers it.
Some vendors sell a third component under the same Wolverine label, most often GHK-Cu. At that point the product has become something closer to a Glow blend, and the name has stopped describing the contents. Read the label, not the name.
The Mechanistic Rationale, and Its Limit
The pairing is not arbitrary. The two compounds are associated with different stages of the same tissue repair sequence.
| BPC-157 | TB-500 | |
|---|---|---|
| Primary mechanism studied | Angiogenesis, the formation of new blood vessels, with VEGF signaling most often cited | Actin sequestration, affecting cytoskeletal assembly and cell migration |
| Stage of repair addressed | Blood supply to the damaged area | Movement of repair cells into that area |
| Main model systems | Rodent tendon, ligament, gastrointestinal | Wound, corneal, dermal and cardiac models |
| Evidence depth | Extensive preclinical, effectively no human data | Preclinical, thinner than BPC-157 |
Vascularization plus cell migration is a coherent pairing on paper. Get blood to the site and get repair cells there, and the two functions plausibly complement each other.
Here is the limit, and it is the thing most Wolverine stack content omits. No published study has compared the combination against either compound administered alone. There is no data showing the pairing outperforms BPC-157 by itself, and no data showing it outperforms TB-500 by itself. The synergy claim is a reasonable hypothesis that nobody has tested. Presenting it as an established result, which a great deal of material online does, misrepresents what is known.
What the Research Actually Shows
Both literatures are preclinical. That is not a dismissal, it is a description of what stage the evidence is at.
BPC-157 studies report accelerated healing in transected rodent Achilles tendon and medial collateral ligament models, effects in ulcer and inflammatory bowel models, and consistent angiogenic activity across tissue types. There are no completed controlled human trials establishing efficacy for any indication. Both halves of the stack anchor our guide to peptides for tendon repair.
TB-500 and thymosin beta-4 work centers on actin binding and the cell migration that follows. A caution specific to this compound: studies conducted on full-length thymosin beta-4 are routinely cited as TB-500 evidence. They are related but not interchangeable, and the fragment has a much thinner literature of its own.
The strongest external check on all of this came in July 2026, when FDA’s review team assessed both compounds for the 503A bulks list and recommended against both, citing insufficient clinical safety and efficacy data along with characterization concerns. The advisory committee recommended them anyway, by two votes each. Genuinely contested, in other words, rather than settled in either direction.
Wolverine vs Glow vs KLOW
These three names cover overlapping formulations and get confused constantly. The relationship is simpler than the naming suggests.
| Name | Components | Emphasis | Peaks to verify |
|---|---|---|---|
| Wolverine | BPC-157, TB-500 | Structural repair | 2 |
| Glow | GHK-Cu, BPC-157, TB-500 | Repair plus dermal matrix | 3 |
| KLOW | KPV, GHK-Cu, BPC-157, TB-500 | Repair, matrix, inflammatory signaling | 4 |
Wolverine is the base pair. Glow adds GHK-Cu, a copper-binding tripeptide studied for collagen synthesis. KLOW adds KPV on top of that, an alpha-MSH fragment studied for inflammatory signaling.
Two practical consequences follow. First, verification difficulty rises with each component, because a certificate has to resolve and quantify one more peak. Second, storage becomes a compromise: GHK-Cu is a copper complex and is more sensitive to light and pH than the uncomplexed peptides beside it, so a three or four component vial forces one storage condition on molecules with different requirements. On both counts the two-component Wolverine is the easiest of the three to verify and handle. Our Glow stack analysis works through the three-component case in detail.
Blend or Two Separate Vials?
Two separate vials are the safer default. A pre-blended vial fixes the ratio at whatever the vendor chose and makes its certificate harder to read, whereas separate vials let you verify each peptide on its own analysis and adjust the ratio afterwards. The blend wins on price per vial and on convenience, and on nothing else.
This is the decision most buyers are actually making, and the trade is rarely framed properly.
- Cost. A pre-blended vial usually carries a lower sticker price, but the ratio is fixed at manufacture and you pay for both components whether or not you use them in that proportion.
- Verification. Two separate vials can each be checked against their own certificate. A blend needs one certificate that resolves both peaks, and many certificates issued for blends do not attempt it.
- Ratio control. Separate vials let you set the ratio at reconstitution. A blend does not.
- Handling. A blend is one reconstitution step. Two vials are two, with two chances for arithmetic error.
For a two-component stack the verification argument is weaker than it is for Glow or KLOW, since resolving two peaks is a routine analytical task. The ratio argument is the stronger one: a fixed blend commits you to a manufacturer’s proportion decision that no data supports over any other.
Where to Buy the Wolverine Stack Peptide?
Three vendors we track stock the blend, and all three test independently. LA Peptides is the cheapest way in at $79.99 for the 10mg/10mg format, Ascension runs $90.00 for the same split, and Amino Club’s Wolverine is $149.99 with its lot-matched COA posted on the listing.
| Vendor | Format | Price | Notes |
|---|---|---|---|
| LA Peptides | BPC-157/TB-500 blend, 10mg + 10mg | $79.99 | Third-party COA for every batch (Bioviridian) |
| Ascension | Wolverine Stack, 10mg + 10mg (20mg) | $90.00 | Kovera Labs COA per batch, marked down from $149.99 |
| Amino Club | BPC-157/TB-500 (Wolverine) | $149.99 | 8x ISO 17025 tested, lot-matched COA on the listing, ships same day before 3 PM ET |
Whichever vendor you pick, apply the blend-COA standard from the verification section below: two identified peptides, each with its own quantity, matched to the lot on your vial. Prices were checked the day this section was updated, and everything here is strictly for non-human research use.
On Wolverine Stack Dosage
Wolverine stack dosage is one of the highest-volume searches attached to this topic, and Peptide Insider does not publish dosing charts. The reason is specific rather than a generic disclaimer.
A dose figure is a claim about a dose-response relationship. Neither BPC-157 nor TB-500 has an established one in humans: no dose-ranging studies, no pharmacokinetic characterization, no safety threshold derived from clinical data. And because the combination has never been studied at all, a combined protocol is an inference stacked on two inferences. The charts circulating online are back-calculated from rodent studies using body-surface-area conversions, a method intended for setting a starting dose in a supervised first-in-human trial. Different sources apply it differently, which is why published charts disagree with each other by wide margins.
What is a legitimate laboratory calculation is reconstitution: converting a vial mass and a diluent volume into a concentration per unit volume. For a blend it carries the extra step of splitting the stated total across two components, which the label may not specify. Our reconstitution protocol covers the method and the errors that recur.
Verifying a Wolverine Blend
If you are buying a pre-blended vial, these are the checks that separate documentation from marketing:
- Two resolved peaks on the chromatogram. A single aggregate purity figure for the vial tells you nothing about the split. A vial reporting 99 percent purity could be almost entirely one component.
- Mass spectrometry for each component separately. HPLC establishes purity, mass data establishes identity. For TB-500 specifically, check that the reported mass corresponds to the fragment rather than to full-length thymosin beta-4.
- A stated ratio with quantification behind it. A label reading 10 mg plus 10 mg needs data supporting both numbers.
- Lot matching. The lot on the certificate must be the lot on the vial. A product-line certificate is marketing material.
- A named, independent lab. In-house testing is not third-party verification.
Our certificate of analysis guide covers reading the documents, and the vendor scores rank suppliers on whether their documentation survives this level of scrutiny.
Regulatory Status After July 2026
Both halves of the Wolverine stack moved further through the US regulatory process in 2026 than at any previous point, without either becoming legal to compound.
In April 2026 FDA removed both from Category 2, the designation reserved for nominated substances the agency has determined raise significant safety concerns. On July 23 the Pharmacy Compounding Advisory Committee reviewed both for the Section 503A bulk drug substances list: BPC-157 with ulcerative colitis as the nominated indication, TB-500 with wound healing. Each was recommended by a vote of 8 to 6 with one abstention, against FDA’s own review team.
What has not changed: FDA must publish a proposed rule, take public comment and issue a final rule before either substance reaches the list. Research-grade material sold for laboratory use sits outside the 503A framework entirely. Our breakdown of the July 2026 PCAC vote covers every vote and the timeline.
One market effect worth anticipating: BPC-157 and TB-500 are now the two most-discussed compounds in the compounding conversation, and attention moves pricing before regulation does. Our 2026 price analysis tracks the category.
Our BPC-157 TB-500 dosage calculator splits every draw of a blend vial into its two components by the label ratio, without suggesting an amount.
Frequently Asked Questions
What is the Wolverine stack?
It is the market name for BPC-157 and TB-500 used together, after the comic-book character known for rapid healing. It is not a research designation and carries no standard formulation or ratio.
What is in the Wolverine peptide stack?
BPC-157, a fifteen-amino-acid peptide derived from a gastric juice protein, and TB-500, a synthetic fragment of thymosin beta-4. Some vendors add a third component, usually GHK-Cu, while keeping the same name.
Is the Wolverine stack better than BPC-157 alone?
Unknown. No published study has compared the combination against either compound alone, so there is no evidence supporting the claim in either direction.
Is the Wolverine stack legal?
Both components are unapproved drug substances. An FDA advisory committee recommended both for the 503A compounding list in July 2026, but that recommendation does not make them compoundable and does not change how research-grade material may be sold.
What is the difference between the Wolverine stack and Glow?
Glow is the Wolverine pair plus GHK-Cu. KLOW adds KPV on top of that. Wolverine is the two-component base.
Should I buy a blend or two separate vials?
Two vials give ratio control and simpler verification. A blend is cheaper and involves one reconstitution step. For a two-component stack the verification gap is smaller than it is for three or four component blends.
References
- U.S. Food and Drug Administration. “July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee.” Advisory Committee Calendar and briefing materials.
- Orrick. “FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings to Consider Adding Peptides to 503A Bulk Drug Substances List.” April 2026.
- Hyman, Phelps & McNamara, FDA Law Blog. “The PEPTIDE-L Wave Rolls On! PCAC Adds Two More Bulk Drug Substances for the 503A List.” July 2026.
Peptide Insider publishes market and regulatory analysis for laboratory professionals. This article is informational and is not legal advice, medical advice, or a recommendation to purchase or use any substance. Compounds discussed here are not approved for human use.
Primary sources
- Sikiric P et al. Gastric pentadecapeptide BPC 157. 2019 (PMID 30915550)
- Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. 2021 (PMID 34267654)
- Multifunctionality and Possible Medical Application of BPC 157. 2025 (PMID 40005999)
Leave a Reply